Related Experiment Video
Updated: Feb 27, 2026
Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
Published on: November 10, 2013
Recent development of transition metal complexes with in vivo antitumor activity
Jia-Xin Liang1, Hai-Jing Zhong1, Guanjun Yang1
1State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China.
Abstract:
The often severe side effects displayed by currently used platinum and ruthenium complexes have motivated researchers to design and develop transition metal-based anti-tumor agents with reduced toxicity. Distinct from organic anti-tumor drugs, transition metal complexes possess several properties that render them as promising scaffolds for anti-cancer drug discovery. While a vast number of metal complexes have been synthesized and reported to be promising and potent in vitro anticancer active compounds, fewer have shown efficacy in in vivo models. The demonstration of in vivo potency is an essential step for lead candidates for clinical trials. In this review, we highlight examples of transition metal-based complexes that have shown in vivo anti-tumor activities that have been described in recent years.
Insights
Researchers are developing new transition metal complexes as anti-cancer drugs to reduce severe side effects. This review highlights metal-based compounds demonstrating in vivo anti-tumor activity, a key step for clinical trials.
Area of Science:
- Medicinal Chemistry
- Oncology
- Materials Science
Background:
- Current platinum and ruthenium anti-cancer drugs cause severe side effects.
- Transition metal complexes offer unique properties for developing novel anti-cancer agents.
- Demonstrating in vivo efficacy is crucial for advancing potential cancer drugs.
Purpose of the Study:
- To review recent advances in transition metal-based complexes with in vivo anti-tumor activity.
- To highlight promising metal-based compounds as potential anti-cancer therapeutics.
- To bridge the gap between in vitro findings and in vivo validation for anti-cancer drug discovery.
Main Methods:
- Literature review of recent scientific publications.
- Focus on transition metal complexes exhibiting anti-tumor effects in vivo.
- Analysis of studies demonstrating efficacy in preclinical models.
Main Results:
- Several transition metal complexes have shown significant in vivo anti-tumor activity.
- These complexes represent diverse metal centers and ligand designs.
- Examples provided showcase potential for reduced toxicity compared to existing therapies.
Conclusions:
- Transition metal complexes are promising candidates for next-generation anti-cancer drugs.
- In vivo anti-tumor activity is a critical benchmark for clinical translation.
- Continued research in this area holds potential for improved cancer treatments.
